US Stem Cell Inc (USRM)

[Archery Class]

Ah yes, RMAT. The big ‘what if’ of this company.

On RMAT hype alone, the price kissed .17. In the best case scenario, they’ve made nice with federal oversight requirements and can resume attempts to secure approval.

We can safely assume any trifles with the FDA in the past have been put to rest. We’re many months past the deadline for compliance, with no further negative actions taken by the FDA. This is a big plus I don’t see discussed too often, but it bodes well that USRM is both expanding and complying.